newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

  • MapLight Therapeutics completed enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, with topline results expected by mid-August 2026.
  • The final patient visit occurred for the Phase 2 IRIS trial of ML-004 in autism spectrum disorder, with topline results also expected by mid-August 2026.
  • Enrollment remains ongoing for the Phase 2 VISTA trial of ML-007C-MA in Alzheimer's disease psychosis, with top-line results anticipated in the second half of 2027.
  • The company held $395.2 million in cash, cash equivalents, & investments as of March 31, 2026, which is projected to fund operations through 2027.
  • Research & development expenses rose to $53.7 million for Q1 2026 from $19.8 million in the prior year period, driven by increased clinical trial & employee-related costs.
  • General & administrative expenses increased to $10.8 million for Q1 2026 from $3.8 million in the prior year period, primarily due to higher employee-related expenses & professional fees.
  • The company reported a net loss of $60.7 million for the first quarter of 2026, compared to a net loss of $22.3 million in the same period last year.
  • ML-007C-MA received Fast Track designation from the FDA in December 2025 for treating hallucinations & delusions associated with Alzheimer's disease psychosis.